InsidersTradesSigma
Total declarations
Company
▲ Purchases (14 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
14
Disclosed sells
0
T+90 hit rate
67%
T+90 mean return
-1.9%
Across 9 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Debbink Dirk J, Chairman & CEO. Director active across 1 company, notably Cincinnati Financial CORP. In total, 20 filings have been published. Breakdown: 14 buys · 0 sell. Total volume traded: €1.3m. History available since 9 August 2021. The latest transaction was disclosed on 30 January 2025 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Declarations20 total
971 shares0Common StockSEC:0001562180-25-000801:0
1,000 shares@ US$157.187811.7% of flowCommon StockSEC:0001562180-24-008299:0
Ideal exit: 30 Aug 2025 (T+270)
1,000 shares@ US$157.187811.7% of flowCommon StockSEC:0001562180-24-008176:0
Ideal exit: 30 Aug 2025 (T+270)
1,000 shares@ US$113.478.3% of flowCommon StockSEC:0001562180-24-003667:0
Ideal exit: 24 Jan 2025 (T+270)
889 shares0Common StockSEC:0001562180-24-000746:0
2,000 shares@ US$102.979814.8% of flowCommon StockSEC:0001562180-23-008193:0
Ideal exit: 31 Aug 2024 (T+270)
1,000 shares@ US$98.78097.3% of flowCommon StockSEC:0001562180-23-007471:0
Ideal exit: 26 Jul 2024 (T+270)
1,000 shares@ US$98.397.2% of flowCommon StockSEC:0001562180-23-004569:0
Ideal exit: 19 Feb 2024 (T+270)
950 shares0Common StockSEC:0001562180-23-000711:0
1,000 shares@ US$106.12997.9% of flowCommon StockSEC:0001562180-22-008152:0
Ideal exit: 2 Sept 2023 (T+270)
510 shares@ US$96.663.8% of flowCommon StockSEC:0001562180-22-005811:0
Ideal exit: 25 Apr 2023 (T+270)
410 shares@ US$120.6670.0002% mcap13.3% of flowCommon StockSEC:0001562180-22-004359:0
Ideal exit: 14 Feb 2023 (T+270)
400 shares@ US$123.280.0002% mcap12.6% of flowCommon StockSEC:0001562180-22-002388:0
Ideal exit: 28 Nov 2022 (T+270)
867 shares0Common StockSEC:0001562180-22-000784:0
867 shares0Common StockSEC:0001562180-22-000784
855 shares@ US$116.81040.0003% mcap25.1% of flowCommon StockSEC:0001562180-21-007356:0
Ideal exit: 26 Aug 2022 (T+270)
855 shares@ US$116.81046.9% of flowCommon StockSEC:0001562180-21-007356
Ideal exit: 26 Aug 2022 (T+270)
419 shares@ US$118.7320.0002% mcap12.0% of flowCommon StockSEC:0001562180-21-005283:0
Ideal exit: 6 May 2022 (T+270)
419 shares@ US$118.7323.3% of flowCommon StockSEC:0001562180-21-005283
Ideal exit: 6 May 2022 (T+270)
1,289 sharesCommon StockSEC:0001127602-16-038686:0
20 of 20 declarations
About Debbink Dirk J
Dan Yrigoyen is the Chief Executive Officer and Vice President of Sales at Arch Therapeutics, Inc. In this role, he oversees the operations and strategy of the company, focusing on sales growth and innovation. Dan is responsible for strategic direction and customer relationship management, playing a key role in the company's development.
